Anebulo Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.05, beating the estimate of USD -0.12.

EBIT: As of FY2026 Q1, the actual value is USD -2.352 M.

Financial Metrics by Segment

Segment Revenue

• No revenue generated since inception.

Operational Metrics

• Net Loss: - $2,158,354 for the three months ended September 30, 2025, compared to - $2,200,736 for the same period in 2024.
• Research and Development Expenses: $809,991 for the three months ended September 30, 2025, compared to $1,314,859 for the same period in 2024.
• General and Administrative Expenses: $1,450,269 for the three months ended September 30, 2025, compared to $1,097,265 for the same period in 2024.
• Total Operating Expenses: $2,260,260 for the three months ended September 30, 2025, compared to $2,412,124 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $1,273,076 for the three months ended September 30, 2025, compared to - $1,689,989 for the same period in 2024.

Unique Metrics

• Grant Income: $9,825 for the three months ended September 30, 2025, compared to $245,362 for the same period in 2024.
• Interest Income: $109,616 for the three months ended September 30, 2025, compared to $26,006 for the same period in 2024.
• Interest Expense: $17,439 for the three months ended September 30, 2025, compared to $59,697 for the same period in 2024.

Future Outlook and Strategy

Core Business Focus

• The company is prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with unintentional cannabis poisoning, which is believed to offer a faster timeline to approval relative to the adult oral product.
• The company has initiated a single ascending dose (SAD) study of IV selonabant in healthy adults in the third quarter of calendar 2025.
• The company expects to continue generating operating losses and will seek additional funding through equity and debt financings or through collaboration, license, and development agreements.

Non-Core Business

• The company is considering a going private transaction, including a reverse stock split, to delist from Nasdaq and deregister its common stock under the Exchange Act.
• The company is reviewing all strategic alternatives available, including the proposed going private transaction, alternative going private transactions, a sale of assets, and/or a merger transaction.

Priority

• The company expects that its cash and cash equivalents at September 30, 2025, along with access to the amount under the Loan Agreement, will enable it to fund its current and planned operating expenses and capital expenditures for at least the next 12 months from the filing of this Quarterly Report.